Literature DB >> 23179584

Expression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma: relationship with clinicopathological characteristics and prognosis.

N Eiró1, C Ovies1, B Fernandez-Garcia1, C C Álvarez-Cuesta2, L González1, L O González1,3, F J Vizoso4,5.   

Abstract

Toll-like receptors (TLRs) have achieved an extraordinary amount of interest in cancer research due to their role in tumor progression. The aim of this study was to investigate the expression and clinical relevance of TLR3, 4, 7 and 9 in cutaneous malignant melanoma (CMM). The expression levels of TLR3, 4, 7 and 9 were analyzed in tumors from 30 patients with CMM. The analysis was performed by immunohistochemistry, and the results were correlated with various clinicopathological findings and with relapse-free survival. Our results indicate that there was a wide variability in the immunostaining score values for each receptor. Positive staining for TLRs was generally found in tumor cells, especially for TLR4 and TLR9. Nevertheless, a significant percentage of tumors also showed TLR4 expression in mononuclear inflammatory cells (62.1 %) and in fibroblast-like cells (34.5 %). Our results showed no significant association between score values for each TLR and clinicopathological characteristics of patients. However, our results demonstrated that high TLR4 expression was significantly associated with a shortened relapse-free survival (p = 0.001). Therefore, TLR4 expression may be a new prognostic factor of unfavorable evolution in cutaneous malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23179584     DOI: 10.1007/s00403-012-1300-y

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  16 in total

1.  TLR4 in skin cancer: From molecular mechanisms to clinical interventions.

Authors:  Sally E Dickinson; Georg T Wondrak
Journal:  Mol Carcinog       Date:  2019-04-24       Impact factor: 4.784

Review 2.  Targeting the PD-1 pathway: a promising future for the treatment of melanoma.

Authors:  Andrew Mamalis; Manveer Garcha; Jared Jagdeo
Journal:  Arch Dermatol Res       Date:  2014-03-11       Impact factor: 3.017

3.  Functional annotation of melanoma risk loci identifies novel susceptibility genes.

Authors:  Shenying Fang; Jiachun Lu; Xinke Zhou; Yuling Wang; Merrick I Ross; Jeffrey E Gershenwald; Janice N Cormier; Jennifer Wargo; Dawen Sui; Christopher I Amos; Jeffrey E Lee
Journal:  Carcinogenesis       Date:  2020-06-17       Impact factor: 4.944

Review 4.  Microbial-Derived Toll-like Receptor Agonism in Cancer Treatment and Progression.

Authors:  Eileena F Giurini; Mary Beth Madonna; Andrew Zloza; Kajal H Gupta
Journal:  Cancers (Basel)       Date:  2022-06-14       Impact factor: 6.575

5.  TLR7 Gln11Leu single nucleotide polymorphism and susceptibility to cutaneous melanoma.

Authors:  Lisa Elefanti; Giorgia Sacco; Camilla Stagni; Marco Rastrelli; Chiara Menin; Irene Russo; Mauro Alaibac
Journal:  Oncol Lett       Date:  2016-05-16       Impact factor: 2.967

Review 6.  Toll-like receptors: exploring their potential connection with post-operative infectious complications and cancer recurrence.

Authors:  S D Gowing; J J Cool-Lartigue; J D Spicer; A J E Seely; L E Ferri
Journal:  Clin Exp Metastasis       Date:  2020-01-23       Impact factor: 5.150

7.  Association between Toll-like receptor 7 Gln11Leu single-nucleotide polymorphism and basal cell carcinoma.

Authors:  Irene Russo; Camilla Cona; Andrea Saponeri; Franco Bassetto; Vincenzo Baldo; Mauro Alaibac
Journal:  Biomed Rep       Date:  2016-02-15

8.  Brucella spp. Lumazine Synthase Induces a TLR4-Mediated Protective Response against B16 Melanoma in Mice.

Authors:  Andrés H Rossi; Ana Farias; Javier E Fernández; Hernán R Bonomi; Fernando A Goldbaum; Paula M Berguer
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

Review 9.  Trial Watch: Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Alexander Eggermont; Catherine Sautès-Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-06-10       Impact factor: 8.110

Review 10.  Toll-like receptors and skin cancer.

Authors:  Erin M Burns; Nabiha Yusuf
Journal:  Front Immunol       Date:  2014-03-31       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.